ReAlta Announces Promising Phase 2 Data Demonstrating Rapid Clinical Responses and Target Engagement…

NORFOLK, Va.–(BUSINESS WIRE)–ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced a presentation of interim…


Click here to view the original article.